Health Care·Biotechnology·$2.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.71 | N/A | +43.43% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.71 | N/A | +43.43% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook, emphasizing the importance of ongoing clinical trials. They highlighted their commitment to innovation in the face of market pressures.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on advancing its pipeline despite the current challenges.
Sarepta Therapeutics reported a wider-than-expected loss per share, which surprised analysts positively, but the lack of revenue data and guidance contributed to a stock decline of nearly 5%. Investors may be concerned about the company's future performance without clear revenue expectations. The stock reaction reflects uncertainty in the market regarding the company's growth trajectory and pipeline developments.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
FOMENTO ECONOMICO ME ADR
Feb 27, 2017